GSK plc GSK announced that the European Medicines Agency has accepted its marketing authorization application (MAA) seeking approval of its investigational ileal bile acid transporter (“IBAT”) ...

EMA accepts GSK’s MAA for linerixibat for cholestatic pruritus in patients with primary biliary cholangitis: London, UK Tuesday, June 24, 2025, 09:00 Hrs [IST] GSK plc announced ...

The EMA has started a review of GSK's treatment candidate for primary biliary cholangitis (PBC), linerixibat, offering hope ...

Linerixibat currently holds orphan drug designation in the US and EU and remains under review for approval globally. GSK is currently trading at $37.99, down $0.08 or 0.22 percent on the New York ...

Linerixibat, a targeted inhibitor of the ileal bile acid transporter (IBAT), is not currently approved in any country. It is also under regulatory review in the US and UK.

· If approved, linerixibat could address high unmet medical need of patients living with cholestatic pruritus (relentless itch) and related sleep interference · Submission based on data from ...

GSK (LSE:GSK) announced that the European Medicines Agency accepted its regulatory application to expand the use of its RSV ...

Linerixibat is currently under regulatory review in the US and UK. GLISTEN is a double-blind, randomised, placebo-controlled, phase III trial (NCT04950127; GSK study 212620) conducted in 238 PBC ...

A regulatory filing seeking approval for linerixibat for the given indication is currently under review in the United States. A final decision from the FDA is expected on March 24, 2026.